Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics (TVTX) reported an insider transaction by its Chief Commercial Officer. On 10/28/2025, the officer sold 2,662 shares of common stock at $30 per share (transaction code S), leaving 124,662 shares beneficially owned directly after the sale.
The filing notes the sale was made under a Rule 10b5-1(c) trading plan adopted on June 16, 2025.
Travere Therapeutics (TVTX) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The materials are included as Exhibit 99.1 and are furnished under Item 2.02, meaning they are not deemed filed for Section 18 liability. The company also included Exhibit 104, the cover page iXBRL data file.
Travere’s common stock trades on the Nasdaq Global Market under the symbol TVTX.
Peter Heerma, Chief Commercial Officer of Travere Therapeutics (TVTX), reported a charitable gift of 891 shares of common stock on 09/23/2025. The gift was made to a donor advised fund under a written plan adopted on June 16, 2025 and is described as complying with Rule 10b5-1(c). After the transaction, Heerma beneficially owned 127,324 shares of Travere common stock. The Form 4 was signed by attorney-in-fact Elizabeth E. Reed on 09/24/2025. The filing indicates the transaction was a non-derivative, zero-price disposition (charitable transfer) and does not report any exercise, purchase, or sale for cash.
Elizabeth E. Reed, Chief Legal Officer and General Counsel of Travere Therapeutics (TVTX), reported simultaneous option exercise and sale transactions on 09/22/2025. She exercised an employee stock option to acquire 10,000 shares at an exercise price of $19.08, increasing her direct beneficial ownership to 99,878 shares. On the same date she sold 10,000 shares at an average price of $25.00 under a pre-established Rule 10b5-1 trading plan adopted 06/16/2025; the sold shares relate to an option grant dated 01/04/2017 that expires 01/04/2027. The option was fully vested and exercisable.
Form 144 notice for Travere Therapeutics, Inc. (TVTX) reports a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $250,000.00. The filing states the shares were acquired and will be sold on 09/22/2025 via a stock option exercise from the issuer, with payment in cash. The issuer's outstanding shares are listed as 89,138,673. The filer reports no securities sold in the past three months. Several identifying fields (filer CIK and contact details) are blank in the provided text.
Travere Therapeutics reports that the U.S. FDA has informed the company an advisory committee is no longer needed for its supplemental new drug application (sNDA) for FILSPARI in focal segmental glomerulosclerosis (FSGS). The sNDA remains under review with a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026.
If approved, FILSPARI would be the first medication indicated for FSGS, a rare kidney disorder that causes protein in the urine and progressive kidney damage. The filing highlights Phase 3 DUPLEX and Phase 2 DUET studies, where FILSPARI showed rapid, superior and sustained reductions in proteinuria versus maximally dosed irbesartan in adult and pediatric patients, and a safety profile comparable to irbesartan.
The DUPLEX study showed statistically significant and clinically meaningful proteinuria remission at 36 weeks that was durable through 2 years, and patients achieving partial or complete remission had a 67% to 77% lower risk of kidney failure. FILSPARI is already fully approved in the U.S. and EU to slow kidney function decline in adults with IgA nephropathy.
Christopher R. Cline, Chief Financial Officer of Travere Therapeutics, sold 470 shares of the company's common stock on 08/27/2025 at a price of $17.31 per share under a written plan intended to satisfy Rule 10b5-1(c). The filing reports 92,656 shares beneficially owned by Mr. Cline after the transaction.
The sale was executed pursuant to a 10b5-1 plan adopted on May 28, 2025 and included additional shares sold to cover the tax obligation arising from the vesting of performance-based restricted stock units that vested in May 2025. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 08/28/2025.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 8,876,000 shares of Travere Therapeutics (TVTX), representing 9.96% of the outstanding common stock. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and exercises shared voting and dispositive power over the shares. Mr. Steven Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The percent ownership is calculated using 89,138,673 shares outstanding as of July 31, 2025, per the issuers SEC filing.
Selected financial highlights (three and six months ended June 30, 2025): Total revenue was $114.4 million for Q2 and $196.2 million for the six months. Net product sales were $94.8 million in Q2 (FILSPARI $71.9M, tiopronin $23.0M) vs. $52.2M a year ago. License and collaboration revenue included a $17.5 million regulatory milestone. Operating loss for the quarter was $12.7M; six-month net loss was $53.98M (basic/diluted loss per share YTD $0.61). Cash and cash equivalents were $75.2M and available-for-sale marketable debt securities were $244.4M (total liquid investments $319.5M). Total assets were $555.3M, total liabilities $522.6M, and stockholders' equity $32.7M.
Operational and programmatic items: FILSPARI previously received full U.S. approval (Sept 5, 2024) and the European conditional MA converted to a standard MA in April 2025, triggering the $17.5M milestone in May 2025. The company submitted an sNDA seeking FSGS approval; the FDA accepted the sNDA and set a PDUFA date of Jan 13, 2026 and plans an advisory committee. Pegtibatinase enrollment is on a voluntary pause due to manufacturing scale-up issues. Renalys licensing and other collaborations remain active.